Schonfeld Strategic Advisors’s Mersana Therapeutics MRSN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.68M | Sell |
226,954
-77,609
| -25% | -$574K | 0.01% | 997 |
|
|
2025
Q1 | $2.62M | Buy |
304,563
+219,780
| +259% | +$1.89M | 0.02% | 723 |
|
|
2024
Q4 | $3.03M | Sell |
84,783
-4,149
| -5% | -$148K | 0.02% | 627 |
|
|
2024
Q3 | $4.2M | Sell |
88,932
-30,145
| -25% | -$1.42M | 0.03% | 503 |
|
|
2024
Q2 | $5.98M | Buy |
119,077
+78,731
| +195% | +$3.96M | 0.04% | 434 |
|
|
2024
Q1 | $4.52M | Sell |
40,346
-5,230
| -11% | -$586K | 0.03% | 571 |
|
|
2023
Q4 | $2.64M | Buy |
+45,576
| New | +$2.64M | 0.02% | 652 |
|
|
2023
Q3 | – | Sell |
-12,822
| Closed | -$1.05M | – | 1924 |
|
|
2023
Q2 | $1.05M | Buy |
+12,822
| New | +$1.05M | 0.01% | 933 |
|
|
2022
Q4 | – | Sell |
-3,446
| Closed | -$583K | – | 2758 |
|
|
2022
Q3 | $583K | Buy |
+3,446
| New | +$583K | ﹤0.01% | 1624 |
|
|
2022
Q2 | – | Sell |
-2,116
| Closed | -$211K | – | 2721 |
|
|
2022
Q1 | $211K | Buy |
+2,116
| New | +$211K | ﹤0.01% | 1855 |
|
|
2021
Q3 | – | Sell |
-900
| Closed | -$306K | – | 2195 |
|
|
2021
Q2 | $306K | Sell |
900
-936
| -51% | -$318K | ﹤0.01% | 1417 |
|
|
2021
Q1 | $743K | Sell |
1,836
-4,297
| -70% | -$1.74M | 0.01% | 964 |
|
|
2020
Q4 | $4.08M | Buy |
6,133
+2,427
| +65% | +$1.61M | 0.05% | 420 |
|
|
2020
Q3 | $1.73M | Buy |
3,706
+1,729
| +87% | +$805K | 0.03% | 511 |
|
|
2020
Q2 | $1.16M | Buy |
1,977
+357
| +22% | +$209K | 0.03% | 533 |
|
|
2020
Q1 | $236K | Buy |
1,620
+1,200
| +286% | +$175K | 0.01% | 850 |
|
|
2019
Q4 | $60K | Buy |
+420
| New | +$60K | ﹤0.01% | 1228 |
|
|
2018
Q2 | – | Sell |
-418
| Closed | -$165K | – | 875 |
|
|
2018
Q1 | $165K | Buy |
+418
| New | +$165K | 0.01% | 692 |
|
|
2017
Q3 | – | Sell |
-1,400
| Closed | -$489K | – | 695 |
|
|
2017
Q2 | $489K | Buy |
+1,400
| New | +$489K | 0.05% | 394 |
|